Philippe Armand, MD
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Philippe Armand, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 02:00 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01746173 · CHOEP + High Dose Therapy + Auto SCT for T-Cell LymphomaDana-Farber Cancer Institute · terminated · T-cell Non-Hodgkin Lymphoma · principal investigator
- N/ANCT00954720 · Observational Study of Iron Overload in Stem Cell TransplantationDana-Farber Cancer Institute · completed · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome · principal investigator
- Ph3NCT00928018 · Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With LymphomaDana-Farber Cancer Institute · completed · Non-hodgkin Lymphoma, Hodgkin Lymphoma · principal investigator
- N/ANCT00658411 · Deferoxamine for Iron Overload Before Allogeneic Stem Cell TransplantationDana-Farber Cancer Institute · terminated · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 02:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.